Download PDF
Klin Monbl Augenheilkd 2022; 239(08): 1033-1042
DOI: 10.1055/a-1473-5713
Übersicht

The Challenges of Treating Neovascular Age-Related Macular Degeneration

Article in several languages: English | deutsch
Marlene Hollaus 
1   Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Österreich
2   Forschungszentrum Vienna Clinical Trial Center, Medizinische Universität Wien, Österreich
,
Wolf Bühl
1   Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Österreich
,
Ursula Schmidt-Erfurth
1   Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Österreich
,
Stefan Sacu
1   Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Österreich
2   Forschungszentrum Vienna Clinical Trial Center, Medizinische Universität Wien, Österreich
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Age-related macular degeneration (AMD) is one of the main causes of visual impairment and blindness in patients over 60 years in developed countries. Whilst no effective form of therapy is available for the dry form of AMD, intravitreal application of anti-VEGF substances is able to prevent the progression of neovascular AMD (nAMD) in most cases. Aside from the drugs ranibizumab, aflibercept and brolucizumab, other agents such as bevacizumab are often used off-label in order to save expense. The treatment intervals have also been refined, so as to reduce the burden on patients and health care systems. After fixed injection intervals, the pro re nata-regimen has been developed. Each month, it is decided whether the patient receives intravitreal injections based on fixed criteria. In the treat and extend-protocol, patients receive injections on each visit, but the intervals between injections vary due to the clinical outcomes. The observe-and-plan regime allows scheduling of the injection intervals in blocks, for three consecutive injections at a time. However, results of real-world studies were not able to reproduce those obtained in the pivotal studies. A high number of visits and fear of the injection procedure impose a burden on patients, that is mostly accepted due to fear of vision loss. Caregivers also complain of loss of productivity and income from having to provide regular support to patients. Health care systems worldwide are affected by increasing treatment numbers and the costs involved. The treatment of nAMD constitutes an achievement for modern medicine. However, despite the challenges, it must be evaluated and reviewed repeatedly in order to provide the best therapy for patients.

Key words

age-related macular degeneration - choroidal neovascularisation - intravitreal therapy - health care system


Publication History

Received: 06 October 2020

Accepted: 27 February 2021

Article published online:
01 July 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Flaxman SR, Bourne RRA, Resnikoff S. et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 2017; 5: e1221-e1234
    CrossrefPubMedSearch in Google Scholar
  • 2 Colijn JM, Buitendijk GHS, Prokofyeva E. et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology 2017; 124: 1753-1763
    CrossrefPubMedSearch in Google Scholar
  • 3 Schmidt-Erfurth UM, Richard G, Augustin A. et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007; 85: 486-494
    CrossrefPubMedSearch in Google Scholar
  • 4 Boyle J, Vukicevic M, Koklanis K. et al. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 2018; 23: 127-140
    CrossrefPubMedSearch in Google Scholar
  • 5 Baxter JM, Fotheringham AJ, Foss AJE. Determining patient preferences in the management of neovascular age-related macular degeneration: A conjoint analysis. Eye (Lond) 2016; 30: 698-704
    CrossrefPubMedSearch in Google Scholar
  • 6 Grzybowski A, Told R, Sacu S. et al. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica 2018; 239: 181-193
    Search in Google Scholar
  • 7 Sacu S, Michels S, Prager F. et al. Randomised clinical trial of intravitreal Avastin vs. photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009; 23: 2223-2227
    CrossrefPubMedSearch in Google Scholar
  • 8 Maberley D. Pegaptanib for neovascular age-related macular degeneration. Issues Emerg Health Technol 2005; (76) 1-4
    CrossrefPubMedSearch in Google Scholar
  • 9 VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.). Chakravarthy U, Adamis AP, Cunningham jr. ET. et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508.e1-1508.e25
    CrossrefPubMedSearch in Google Scholar
  • 10 Brown DM, Kaiser PK, Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
    CrossrefPubMedSearch in Google Scholar
  • 11 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
    CrossrefPubMedSearch in Google Scholar
  • 12 Heier JS, Brown DM, Chong V. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548
    CrossrefPubMedSearch in Google Scholar
  • 13 Martin DF, Maguire MG, Ying GS. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908
    CrossrefPubMedSearch in Google Scholar
  • 14 Bro T, Derebecka M, Jørstad ØK. et al. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol 2020; 258: 503-511
    CrossrefPubMedSearch in Google Scholar
  • 15 Parikh R, Pirakitikulr N, Chhablani J. et al. A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. Ophthalmol Retina 2019; 3: 16-26
    CrossrefPubMedSearch in Google Scholar
  • 16 Singh SR, Dogra A, Stewart M. et al. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. Asia Pac J Ophthalmol (Phila) 2017; 6: 561-568
    CrossrefPubMedSearch in Google Scholar
  • 17 Khanna S, Komati R, Eichenbaum DA. et al. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: A comparative review. BMJ Open Ophthalmol 2019; 4: e000398
    CrossrefPubMedSearch in Google Scholar
  • 18 Ammar MJ, Hsu J, Chiang A. et al. Age-related macular degeneration therapy: a review. Curr Opin Ophthalmol 2020; 31: 215-221
    CrossrefPubMedSearch in Google Scholar
  • 19 Hufendiek K, Pielen A, Framme C. [Strategies of Intravitreal Injections with Anti-VEGF: “Pro re Nata versus Treat and Extend”]. Klin Monbl Augenheilkd 2018; 235: 930-939
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Mantel I, Niderprim SA, Gianniou C. et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 2014; 98: 1192-1196
    CrossrefPubMedSearch in Google Scholar
  • 21 Eleftheriadou M, Gemenetzi M, Lukic M. et al. Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. Ophthalmol Ther 2018; 7: 361-368
    CrossrefPubMedSearch in Google Scholar
  • 22 Rofagha S, Bhisitkul RB, Boyer DS. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120: 2292-2299
    CrossrefPubMedSearch in Google Scholar
  • 23 Berg K, Roald AB, Navaratnam J. et al. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol 2017; 95: 796-802
    CrossrefPubMedSearch in Google Scholar
  • 24 Ozkaya A, Alagoz C, Garip R. et al. The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting. Eye (Lond) 2016; 30: 958-965
    CrossrefPubMedSearch in Google Scholar
  • 25 Ramos MS, Xu LT, Singuri S. et al. Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors. Ophthalmol Retina 2020;
    CrossrefPubMedSearch in Google Scholar
  • 26 Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013; 27: 787-794
    CrossrefPubMedSearch in Google Scholar
  • 27 Rosenfeld PJ, Browning DJ. Reply to Comment on: “Is this a 737 Max Moment for Brolucizumab?”. Am J Ophthalmol 2020; 223: 446-447
    CrossrefPubMedSearch in Google Scholar
  • 28 Daien V, Nguyen V, Essex RW. et al. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology 2018; 125: 66-74
    CrossrefPubMedSearch in Google Scholar
  • 29 Droege KM, Muether PS, Hermann MM. et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 2013; 251: 1281-1284
    CrossrefPubMedSearch in Google Scholar
  • 30 Chen X, Seth RK, Rao VS. et al. Effects of music therapy on intravitreal injections: A randomized clinical trial. J Ocul Pharmacol Ther 2012; 28: 414-419
    CrossrefPubMedSearch in Google Scholar
  • 31 Weyer-Wendl H, Walter P. Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration. Health Econ Rev 2016;
    CrossrefPubMedSearch in Google Scholar
  • 32 Hanemoto T, Hikichi Y, Kikuchi N. et al. The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLoS One 2017; 12: e0189035
    CrossrefPubMedSearch in Google Scholar
  • 33 Williams G. IVT injections: health policy implications. Rev Ophthalmol 2014; 21: 62-64
    PubMedSearch in Google Scholar
  • 34 Schwabe U, Paffrath D, Ludwig WD, Klauber J. Hrsg. Arzneiverordnungs-Report 2019. Berlin: Springer; 2019
    CrossrefSearch in Google Scholar
  • 35 Prenner JL, Halperin LS, Rycroft C. et al. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings from a Time-and-Motion Study. Am J Ophthalmol 2015; 160: 725-731.e1
    CrossrefPubMedSearch in Google Scholar
  • 36 Mulligan K, Seabury SA, Dugel PU. et al. Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients with Wet Age-Related Macular Degeneration in the United States. JAMA Ophthalmol 2019; 138: 40-47
    CrossrefPubMedSearch in Google Scholar
  • 37 Hollingworth W, Jones T, Reeves BC. et al. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open 2017; 7: e018289
    CrossrefPubMedSearch in Google Scholar
  • 38 Starr MR, Barkmeier AJ, Engman SJ. et al. Telemedicine in the Management of Exudative Age-Related Macular Degeneration within an Integrated health care System. Am J Ophthalmol 2019; 208: 206-210
    CrossrefPubMedSearch in Google Scholar
  • 39 Andonegui J, Aliseda D, Serrano L. et al. Evaluation of a telemedicine model to follow up patients with exudative age-related macular degeneration. Retina 2016; 36: 279-284
    CrossrefPubMedSearch in Google Scholar
  • 40 Holekamp NM. Moving From Clinic to Home: What the Future Holds for Ophthalmic Telemedicine. Am J Ophthalmol 2018; 187: xxviii-xxxv
    CrossrefPubMedSearch in Google Scholar
  • 41 Rim TH, Cheng CY, Kim DW. et al. A nationwide cohort study of cigarette smoking and risk of neovascular age-related macular degeneration in East Asian men. Br J Ophthalmol 2017; 101: 1367-1373
    CrossrefPubMedSearch in Google Scholar
  • 42 Treder M, Eter N. [Chances of Artificial Intelligence and Big Data for the Diagnosis and Treatment of Age-related Macular Degeneration]. Klin Monbl Augenheilkd 2019; 236: 1418-1422
    Thieme ConnectPubMedSearch in Google Scholar
  • 43 Grassmann F, Mengelkamp J, Brandl C. et al. A Deep Learning Algorithm for Prediction of Age-Related Eye Disease Study Severity Scale for Age-Related Macular Degeneration from Color Fundus Photography. Ophthalmology 2018; 125: 1410-1420
    CrossrefPubMedSearch in Google Scholar
  • 44 Schmidt-Erfurth U, Vogl WD, Jampol LM. et al. Application of Automated Quantification of Fluid Volumes to Anti–VEGF Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology 2020; 127: 1211-1219
    CrossrefPubMedSearch in Google Scholar
  • 45 Hahn P, Eliott DE. 2020 Global Trends in Retina Survey. Am Soc Retin Spec 2020. Accessed May 5, 2021 at: https://www.asrs.org/content/documents/2020-global-trends-in-retina-survey-highlights-for-website.pdf
    PubMed
  • 46 van Asten F, Michels CTJ, Hoyng CB. et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration–A cost-effectiveness analysis from a societal perspective. PLoS One 2018; 13: e0197670
    CrossrefPubMedSearch in Google Scholar
  • 47 Cohen D. CCGs win right to offer patients Avastin for wet AMD. BMJ 2018; 362: k4035
    CrossrefPubMedSearch in Google Scholar
  • 48 Simcock P, Kingett B, Mann N. et al. A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners. Eye (Lond) 2014; 28: 1161-1164
    CrossrefPubMedSearch in Google Scholar
  • 49 Toth CA, Decroos FC, Ying GS. et al. Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the comparison of age-related macular degeneration treatments trials. Retina 2015; 35: 1303-1314
    CrossrefPubMedSearch in Google Scholar
  • 50 Bogunovic H, Waldstein SM, Schlegl T. et al. Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach. Invest Ophthalmol Vis Sci 2017; 58: 3240-3248
    CrossrefPubMedSearch in Google Scholar